3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Rituximab
29
Surveys and Questionnaires
25
Blood Specimen Collection
17
Gene Expression Profiling
15
Flow Cytometry
14
Polymerase Chain Reaction
13
Amplified Fragment Length Polymorphism Analysis
13
Microarray Analysis
11
Observation
10
Interviews as Topic
10
Psychiatric Rehabilitation
9
Lenalidomide
9
Immunohistochemistry
9
Cytogenetic Analysis
9
obinutuzumab
8
Watchful Waiting
8
Therapeutics
8
ibrutinib
7
Drug Therapy
7
Cyclophosphamide
7
Bendamustine Hydrochloride
7
Vincristine
6
Prednisone
6
Magnetic Resonance Spectroscopy
6
fludarabine
5
In Situ Hybridization, Fluorescence
5
Immunologic Techniques
5
Data Collection
5
Brentuximab Vedotin
5
Biopsy
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Inosine Monophosphate
×
Lymphoid
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled